Main objective: Comparing effectiveness of high dose atorvastatin versus low dose atorvastatin in cardiovascular outcome after percutaneous coronary intervention (PCI) in patients with stable angina, for prevention of major cardiovascular events-
Method: randomized clinical trial, double blinded, single center, drug intervention- Control group: atorvastatin, tablet 10 mg twice per day oral (standard treatment)- Intervention group: atorvastatin, tablet 40 mg twice per day oral-
Inclusion criteria: patients with stable angina that nominated for coronary angioplasty- Exclusion criteria: acute coronary syndrome (unstable angina, non ST elevation myocardial infarction, ST elevation myocardial infarction), bare stent angioplasty, balloon angioplasty, angioplasty on saphenous vein graft, liver disease- Volume: 469 patients, 6 month fallow up-
Primary outcome measure: major adverse cardiac and cerebrovascular events, all cause mortality, stroke, target lesion revascularization, target vessel revascularization, acute coronary syndrome, at least 3 times increase of liver and or mascular enzymes- Secondary outcome measure: total cholesterol (end of study), LDL (end of study), HDL (end of study), triglyceride(end of study), total cholesterol to HDL (end of study)